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Thombs and colleagues have shown that screening consecutive attendees in primary care settings in high income
countries for depression is not worthwhile. However, it is dangerous to generalize from high income countries such
as the USA to the rest of the world. The positive predictive value of any screening test for depression is affected by
the prevalence of the disorder in the population being considered. Populations with an increased prevalence of
depression, such as those with chronic physical disorders, or with a history of depression or other mental health
problems may benefit from screening, even in high income countries. Populations in low and middle income
countries (LMIC) may also benefit from screening if they are experiencing severe social adversity, including poverty.
Two examples are given, in which screening with a brief screening questionnaire was followed by collaborative
stepped care, to the considerable benefit of the patients in LMIC.
Please see related article: http://www.biomedcentral.com/1741-7015/12/13.
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Thombs and colleagues [1] have brought the argument
about screening consecutive attendees for depression up
to date, but there is really nothing new in their general
conclusion that in high income countries there are no
positive gains in the use of screening tests for depres-
sion. They are correct in saying that the advice of the
US Public Health Service, stating that family physicians
should use such screening tests, is not supported by the
available evidence. It has been known since 2001 that
many studies that merely provided general practitioners
with feedback of high scores on screening question-
naires, have not resulted in increased recognition [2],
and even those studies that did report increased recog-
nition did not lead to better treatment [3,4]. Indeed,
similar findings have been reported from much earlier
studies in primary care [5]. The first National Guideline
of Depression in the UK in 1993 [6] did not recommend
routine screening, but did recommend that screening
should be undertaken in primary care and general hos-
pital settings for depression in high risk groups; for
example, those with a history of depression, significantCorrespondence: davidpgoldberg@yahoo.com
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2014physical illnesses causing disability, or other mental health
problems, such as dementia. The guideline was re-issued
in 1999 [7] with substantially the same advice, advising
clinicians to be alert to possible depression (particularly
in people with a history of depression or a chronic physi-
cal health problem with associated functional impairment)
and consider asking people who may have depression the
two screening questions that are used to define depression
in both the International Classification of Disease [8] and
the Diagnostic and Statistical Manual (DSM) system of
the American Psychiatric Association [9].
The positive predictive value of a screening test
The original National Institute for Health and Clinical
Excellence (NICE) guideline for depression [6] conclu-
ded that high prevalence populations could be screened
with much better results. This is because the proportion
of high scorers on a test which turn out to be true cases
(the positive predictive value, or PPV) is greatly affected
by the point prevalence of the disorder in the screened
population [10]. This is true of any screening test, inclu-
ding the nine-item Patient Health Questionnaire (PHQ-9)
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90% and a specificity of 85% would have a PPV of only
40%, so a clinician could be forgiven for not wishing to
be influenced by a test with such a low chance of being
correct. However, the same test at a prevalence of 45%
would have a PPV of 83.5%. The negative predictive
value is affected to a much smaller degree, being 98.7%
at 10% prevalence, but is a still acceptable 91.2% at a
prevalence of 45%. It can be seen that in high prevalence
populations, the same screening test works very much
better than it does in predominantly healthy populations.
For example, Whooley et al. [11] argue that screening is
worthwhile in all patients with chronic cardiac disease.
Low and middle income countries
Many populations of people seeking care in low and
middle income countries (LMIC) have a high prevalence
of psychological disorders: for example, in the World
Health Organization study [12] of Mental Illness in
General Health Care, the overall point prevalence of
disorders was 52.5% in Santiago de Chile, and 35.5%
in Rio de Janeiro, but below 10% in Verona, Ibadan,
Nagasaki, and Shanghai, and only 11.9% in Seattle. In
both of the South American cities, there was considerable
poverty and social adversity to add to the list of features
known to be associated with high prevalence.
Of course, these high prevalences do not apply to all
settings in LMIC, but they are common wherever social
adversity and poverty are marked, so that use of scree-
ning tests is widespread in these countries. In recent
years, some of the older tests such as the 12-item General
Health Questionnaire (GHQ-12) [13-15], the Symptom
Rating Questionnaire [16], and the Hospital Depression
and Anxiety Scales (HADS) [13] have been used, as well
as more recent instruments such as the PHQ-9 [17] and
the two Kessler scales (K6 and K10) [18,19]. In general,
there is agreement that in these settings, the shorter scales
are as effective as the longer ones [20].
However, two further things are also necessary, other
than a high prevalence of depression in the population
to be screened, and these involve both healthcare provider
and patient The doctor must have the ability to both diag-
nose and assess the severity of the depression, and must
be able to provide effective treatment. It is also helpful if
the doctor is perceived by the patient as someone with
whom it is easy to communicate. The patient must be pre-
pared to admit that they have a need for an intervention,
be allowed to choose what treatment they receive, and to
invest both time and cooperation in such treatment.
Two examples of successful use of screening tests
in LMIC
Both of these examples [14,15] used screening with the
GHQ-12 followed by the use of collaborative stepped care(CSC), and compared care by a lay mental health worker
with the condition of usual care by the primary care clin-
ician, in a randomized controlled trial. In the study by
Patel et al., the CSC condition meant that all patients with
high scores on a screening questionnaire were given
psycho-education by the lay counsellors, but in patients
with higher scores this was supplemented by an antide-
pressant by the primary care physician. Psycho-education
taught patients strategies to alleviate their symptoms,
using techniques such as breathing exercises for anxiety
symptoms and scheduling activities for symptoms of de-
pression. Moderately or severely ill patients who were of-
fered drug treatment could also have group interpersonal
psychotherapy from the lay health worker. A later paper
[21] followed these patients up for 12 months, and found a
30% decrease in the prevalence of common mental disor-
ders among those with baseline ICD-10 diagnoses (risk ra-
tio (RR) = 0.70, 95% CI 0.53 to 0.92); and a similar effect
among the subgroup of participants with depression (RR =
0.76, 95% CI 0.59–0.98). There was a 36% reduction in sui-
cide attempts/plans over 12 months (RR = 0.64, 95% CI
0.42 to 0.98) among baseline ICD-10 cases. Strong effects
were observed on days out of work and psychological
morbidity, and modest effects on overall disability.
In the study by Araya et al. [15], low-income female
patients with severe depression in Santiago, Chile, were
allocated to usual care or to care administered by a
3-month, multi-component intervention led by a non-
medical health worker. At six months’ follow-up, 70%
of the intervention group compared with 30% of the
usual care group, had recovered. A later paper [22] con-
sidered outcome at 6 months and found that, after adjus-
ting for initial severity, women receiving the stepped-care
program had a mean of 50 additional depression-free
days over 6 months relative to patients allocated to
usual care. The CSC program was marginally more expen-
sive than usual care (an extra 216 Chilean pesos per
depression-free day). The authors concluded that small
investments to improve depression appear to yield
larger gains in poorer environments.
Future directions and conclusions
It is to be hoped that future studies in all populations in
which an increased prevalence of depression may be ex-
pected will continue to use brief screening procedures to
detect depression. In LMIC, CSC offered by a trained
non-medical health worker has been shown to produce
excellent results.
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